## Harriet Corvol

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5758615/publications.pdf

Version: 2024-02-01

144 papers 4,837 citations

39 h-index 123376 61 g-index

166 all docs

166
docs citations

166 times ranked 6328 citing authors

#	Article	IF	CITATIONS
1	Atypical Severe Organizing Pneumonia Following Coronavirus Disease 2019 in an Immunocompromised Teenager. Clinical Infectious Diseases, 2022, 74, 938-939.	2.9	3
2	Risk factors for Pseudomonas aeruginosa airway infection and lung function decline in children with cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 45-51.	0.3	8
3	Leveraging TOPMed imputation server and constructing a cohort-specific imputation reference panel to enhance genotype imputation among cystic fibrosis patients. Human Genetics and Genomics Advances, 2022, 3, 100090.	1.0	6
4	Factors Predisposing the Response to Lumacaftor/Ivacaftor in People with Cystic Fibrosis. Journal of Personalized Medicine, 2022, 12, 252.	1.1	3
5	SLC6A14 Impacts Cystic Fibrosis Lung Disease Severity via mTOR and Epithelial Repair Modulation. Frontiers in Molecular Biosciences, 2022, 9, 850261.	1.6	3
6	More on BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. New England Journal of Medicine, 2022, 386, 1191-1193.	13.9	6
7	Respiratory management of spinal muscular atrophy type $1$ patients treated with Nusinersen. Pediatric Pulmonology, 2022, 57, 1505-1512.	1.0	5
8	Cumulative Incidence and Risk Factors for Severe Coronavirus Disease 2019 in French People With Cystic Fibrosis. Clinical Infectious Diseases, 2022, 75, 2135-2144.	2.9	9
9	Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study. Journal of Cystic Fibrosis, 2022, 21, e221-e231.	0.3	15
10	Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function. Journal of Cystic Fibrosis, 2021, 20, 220-227.	0.3	24
11	Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: An international observational study. Journal of Cystic Fibrosis, 2021, 20, 25-30.	0.3	62
12	Chest physiotherapy enhances detection of Pseudomonas aeruginosa in nonexpectorating children with cystic fibrosis. ERJ Open Research, 2021, 7, 00513-2020.	1.1	3
13	Rapid Improvement after Starting Elexacaftor–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 64-73.	2.5	139
14	Infant bronchiolitis dramatically reduced during the second French COVIDâ€19 outbreak. Acta Paediatrica, International Journal of Paediatrics, 2021, 110, 1297-1299.	0.7	25
15	<i>Aci&gt;Achromobacter xylosoxidans</i> airway infection is associated with lung disease severity in children with cystic fibrosis. ERJ Open Research, 2021, 7, 00076-2021.	1.1	15
16	Gene Therapy: A Possible Alternative to CFTR Modulators?. Frontiers in Pharmacology, 2021, 12, 648203.	1.6	4
17	Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020. Journal of Cystic Fibrosis, 2021, 20, 566-577.	0.3	34
18	COVID-19 vaccine prioritisation for people with cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, 715-716.	0.3	5

#	Article	IF	Citations
19	Severe Acute Respiratory Syndrome Coronavirus 2 Variant Delta Infects All 6 Siblings but Spares Comirnaty (BNT162b2, BioNTech/Pfizer)-Vaccinated Parents. Journal of Infectious Diseases, 2021, 224, 1984-1986.	1.9	6
20	Pulmonary Hemorrhage Revealing Multiple Vascular Malformations in a Child with KCNT1 Developmental Epileptic Encephalopathy. Journal of Pediatrics, 2021, 237, 311-312.	0.9	0
21	Cystic fibrosis–related diabetes onset can be predicted using biomarkers measured at birth. Genetics in Medicine, 2021, 23, 927-933.	1.1	17
22	TMEM16A/ANO1: Current Strategies and Novel Drug Approaches for Cystic Fibrosis. Cells, 2021, 10, 2867.	1.8	6
23	642: SLC6A14 is associated with lung function in patients with cystic fibrosis, regulates epithelial repair and mTOR signaling in bronchial epithelial cells. Journal of Cystic Fibrosis, 2021, 20, S305.	0.3	0
24	Benefits and risks of bronchoalveolar lavage in severe asthma in children. ERJ Open Research, 2021, 7, 00332-2021.	1.1	2
25	Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in Europe. ERJ Open Research, 2021, 7, 00411-2021.	1.1	19
26	Creation and validation of a questionnaire assessing quality of life $\hat{A}$ of parents of children with interstitial lung disease (chILD)., 2021,,.		0
27	Flagellin From Pseudomonas aeruginosa Modulates SARS-CoV-2 Infectivity in Cystic Fibrosis Airway Epithelial Cells by Increasing TMPRSS2 Expression. Frontiers in Immunology, 2021, 12, 714027.	2.2	9
28	Hordeum murinum aspiration revealed by a pneumopleurocutaneous fistula in a 15-month-old infant. BMC Pediatrics, 2021, 21, 550.	0.7	2
29	Real-Life Safety and Effectiveness of Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 188-197.	2.5	95
30	Genetic Modifiers of Cystic Fibrosis-Related Diabetes Have Extensive Overlap With Type 2 Diabetes and Related Traits. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1401-1415.	1.8	34
31	Phenotype of children with inconclusive cystic fibrosis diagnosis after newborn screening. Pediatric Pulmonology, 2020, 55, 918-928.	1.0	39
32	Genetic variation in CFTR and modifier loci may modulate cystic fibrosis disease severity. Journal of Cystic Fibrosis, 2020, 19, S10-S14.	0.3	24
33	First Wave of COVID-19 in French Patients with Cystic Fibrosis. Journal of Clinical Medicine, 2020, 9, 3624.	1.0	33
34	Novel Anti-Inflammatory Approaches for Cystic Fibrosis Lung Disease: Identification of Molecular Targets and Design of Innovative Therapies. Frontiers in Pharmacology, 2020, 11, 1096.	1.6	30
35	The Wide Spectrum of COVID-19 Clinical Presentation in Children. Journal of Clinical Medicine, 2020, 9, 2950.	1.0	28
36	The global impact of SARS-CoV-2 in 181 people with cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 868-871.	0.3	74

#	Article	IF	CITATIONS
37	Dramatic improvement after tocilizumab of severe <scp>COVID</scp> â€19 in a child with sickle cell disease and acute chest syndrome. American Journal of Hematology, 2020, 95, E192-E194.	2.0	56
38	A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 355-358.	0.3	113
39	Bronchial Epithelial Cells on the Front Line to Fight Lung Infection-Causing Aspergillus fumigatus. Frontiers in Immunology, 2020, 11, 1041.	2.2	19
40	Variant classifications, databases and genotype-phenotype correlations. Archives De Pediatrie, 2020, 27, eS13-eS18.	0.4	10
41	Update on SLC6A14 in lung and gastrointestinal physiology and physiopathology: focus on cystic fibrosis. Cellular and Molecular Life Sciences, 2020, 77, 3311-3323.	2.4	18
42	Nocturnal hypoventilation in Down syndrome children with or without sleep apnea. Pediatric Pulmonology, 2020, 55, 1246-1253.	1.0	16
43	Atypical presentation of COVID-19 in young infants. Lancet, The, 2020, 395, 1481.	6.3	78
44	Lung ultrasound in children with interstitial lung disease: a pilot study. , 2020, , .		2
45	Mining GWAS and eQTL data for CF lung disease modifiers by gene expression imputation. PLoS ONE, 2020, 15, e0239189.	1.1	9
46	Severe central apnea secondary to cerebellar dysplasia in a child: look past Joubert syndrome. Journal of Clinical Sleep Medicine, 2020, 16, 2113-2116.	1.4	4
47	Retour d'expérience d'un hôpital pédiatrique pendant la crise Covid-19 en Île-de-France. Annales Francaises De Medecine D'Urgence, 2020, 10, 261-265.	0.0	1
48	Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients. Hepatology, 2019, 69, 1648-1656.	3.6	93
49	AGTR2 absence or antagonism prevents cystic fibrosis pulmonary manifestations. Journal of Cystic Fibrosis, 2019, 18, 127-134.	0.3	15
50	Respiratory Epithelial Cells Can Remember Infection: A Proof of Concept Study. Journal of Infectious Diseases, 2019, 221, 1000-1005.	1.9	17
51	SERPINA1 Z allele is associated with cystic fibrosis liver disease. Genetics in Medicine, 2019, 21, 2151-2155.	1.1	25
52	Genetic association and transcriptome integration identify contributing genes and tissues at cystic fibrosis modifier loci. PLoS Genetics, 2019, 15, e1008007.	1.5	56
53	miR-636: A Newly-Identified Actor for the Regulation of Pulmonary Inflammation in Cystic Fibrosis. Frontiers in Immunology, 2019, 10, 2643.	2.2	11
54	Modifier genes in cystic fibrosis-related liver disease. Current Opinion in Gastroenterology, 2019, 35, 88-92.	1.0	32

#	Article	IF	Citations
55	Two-hybrid screening of FAM13A protein partners in lung epithelial cells. BMC Research Notes, 2019, 12, 804.	0.6	6
56	Gas exchanges in children with cystic fibrosis or primary ciliary dyskinesia: A retrospective study. Respiratory Physiology and Neurobiology, 2018, 251, 1-7.	0.7	3
57	<i>Stenotrophomonas maltophilia</i> : A marker of lung disease severity. Pediatric Pulmonology, 2018, 53, 426-430.	1.0	37
58	Whole exome sequencing in three families segregating a pediatric case of sarcoidosis. BMC Medical Genomics, 2018, 11, 23.	0.7	26
59	Improving imputation in disease-relevant regions: lessons from cystic fibrosis. Npj Genomic Medicine, 2018, 3, 8.	1.7	9
60	Airway Mucosal Host Defense Is Key to Genomic Regulation of Cystic Fibrosis Lung Disease Severity. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 79-93.	2,5	46
61	FAM13A is a modifier gene of cystic fibrosis lung phenotype regulating rhoa activity, actin cytoskeleton dynamics and epithelial-mesenchymal transition. Journal of Cystic Fibrosis, 2018, 17, 190-203.	0.3	45
62	CHAC1 Is Differentially Expressed in Normal and Cystic Fibrosis Bronchial Epithelial Cells and Regulates the Inflammatory Response Induced by Pseudomonas aeruginosa. Frontiers in Immunology, 2018, 9, 2823.	2.2	25
63	Emerging microRNA Therapeutic Approaches for Cystic Fibrosis. Frontiers in Pharmacology, 2018, 9, 1113.	1.6	29
64	Human Bronchial Epithelial Cells Inhibit Aspergillus fumigatus Germination of Extracellular Conidia via FleA Recognition. Scientific Reports, 2018, 8, 15699.	1.6	35
65	Opposite Expression of Hepatic and Pulmonary Corticosteroid-Binding Globulin in Cystic Fibrosis Patients. Frontiers in Pharmacology, 2018, 9, 545.	1.6	2
66	Small RNA and transcriptome sequencing reveal the role of miRâ€199aâ€3p in inflammatory processes in cystic fibrosis airways. Journal of Pathology, 2018, 245, 410-420.	2.1	35
67	Pulmonary hemosiderosis in children with Down syndrome: a national experience. Orphanet Journal of Rare Diseases, 2018, 13, 60.	1.2	32
68	SLC26A9 Gene Is Associated With Lung Function Response to Ivacaftor in Patients With Cystic Fibrosis. Frontiers in Pharmacology, 2018, 9, 828.	1.6	29
69	Down syndrome and pulmonary hemosiderosis: an under-recognized association. , 2018, , .		1
70	Prophylactic azithromycin in patients with primary ciliary dyskinesia , $2018, \ldots$		1
71	DNA methylation at modifier genes of lung disease severity is altered in cystic fibrosis. Clinical Epigenetics, 2017, 9, 19.	1.8	29
72	MicroRNA-9 downregulates the ANO1 chloride channel and contributes to cystic fibrosis lung pathology. Nature Communications, 2017, 8, 710.	5.8	56

#	Article	IF	CITATIONS
73	Omalizumab treatment for allergic bronchopulmonary aspergillosis in young patients with cystic fibrosis. Respiratory Medicine, 2017, 133, 12-15.	1.3	28
74	Bronchial Epithelial Cells from Cystic Fibrosis Patients Express a Specific Long Non-coding RNA Signature upon Pseudomonas aeruginosa Infection. Frontiers in Cellular and Infection Microbiology, 2017, 7, 218.	1.8	31
75	Ultrasonography and Computed Tomographic Manifestations of Abdominal Sarcoidosis in Children. Journal of Pediatric Gastroenterology and Nutrition, 2016, 63, 195-199.	0.9	3
76	Novel variation at ${\rm chr}11{\rm p}13$ associated with cystic fibrosis lung disease severity. Human Genome Variation, 2016, 3, 16020.	0.4	9
77	Features of Severe Liver Disease With Portal Hypertension inÂPatients With Cystic Fibrosis. Clinical Gastroenterology and Hepatology, 2016, 14, 1207-1215.e3.	2.4	94
78	Cystic fibrosis gene modifier <i>SLC26A9</i> modulates airway response to CFTR-directed therapeutics. Human Molecular Genetics, 2016, 25, ddw290.	1.4	81
79	Long-term effects of azithromycin in patients with cystic fibrosis. Respiratory Medicine, 2016, 117, 1-6.	1.3	42
80	Are CF carriers predisposed to asthma?. Journal of Cystic Fibrosis, 2016, 15, 555-556.	0.3	0
81	Sources of Variation in Sweat Chloride Measurements in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1375-1382.	2.5	62
82	Surfactant protein A: A key player in lung homeostasis. International Journal of Biochemistry and Cell Biology, 2016, 81, 151-155.	1.2	50
83	Translating the genetics of cystic fibrosis to personalized medicine. Translational Research, 2016, 168, 40-49.	2.2	54
84	French translation and linguistic validation of the QOL-PCD, a quality of life questionnaire for patients with primary ciliary dyskinesia. , $2016,  \ldots$		1
85	Lessons from a French collaborative case–control study in cystic fibrosis patients during the 2009 A/H1N1 influenza pandemy. BMC Infectious Diseases, 2015, 16, 55.	1.3	21
86	Normal and Cystic Fibrosis Human Bronchial Epithelial Cells Infected with Pseudomonas aeruginosa Exhibit Distinct Gene Activation Patterns. PLoS ONE, 2015, 10, e0140979.	1.1	22
87	Vaccine coverage in CF children: A French multicenter study. Journal of Cystic Fibrosis, 2015, 14, 615-620.	0.3	12
88	New Insights about miRNAs in Cystic Fibrosis. American Journal of Pathology, 2015, 185, 897-908.	1.9	37
89	RSPH3 Mutations Cause Primary Ciliary Dyskinesia with Central-Complex Defects and a Near Absence of Radial Spokes. American Journal of Human Genetics, 2015, 97, 153-162.	2.6	88
90	Biomarkers in Interstitial lung diseases. Paediatric Respiratory Reviews, 2015, 16, 219-224.	1.2	20

#	Article	IF	Citations
91	Variants in Solute Carrier SLC26A9 Modify Prenatal Exocrine Pancreatic Damage in Cystic Fibrosis. Journal of Pediatrics, 2015, 166, 1152-1157.e6.	0.9	45
92	Lung sarcoidosis in children: update on disease expression and management. Thorax, 2015, 70, 537-542.	2.7	49
93	Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis. Nature Communications, 2015, 6, 8382.	5.8	242
94	Sweat test practice in pediatric pulmonology after introduction of cystic fibrosis newborn screening. European Journal of Pediatrics, 2015, 174, 1613-1620.	1.3	6
95	A Joint Location-Scale Test Improves Power to Detect Associated SNPs, Gene Sets, and Pathways. American Journal of Human Genetics, 2015, 97, 125-138.	2.6	48
96	Inorganic exposome in pediatric sarcoidosis: The PEDIASARC study. , 2015, , .		1
97	Rare localization of NUT midline carcinoma revealed by pneumonia and pleural effusion in a 13 years old patient: A case report. , 2015, , .		0
98	Gaz exchange, nasal nitric oxyde levels and lung function tests in children with primary ciliary dyskinesia. , $2015, $ , .		0
99	An idiopathic congenital chylothorax: surgery or conservative management?. BMJ Case Reports, 2014, 2014, bcr2014204147-bcr2014204147.	0.2	3
100	Lung disease modifier genes in cystic fibrosis. International Journal of Biochemistry and Cell Biology, 2014, 52, 83-93.	1,2	66
101	HRCT and MRI of the lung in children with cystic fibrosis: Comparison of different scoring systems. Journal of Cystic Fibrosis, 2014, 13, 198-204.	0.3	51
102	Moving beyond genetics: isFAM13Aa major biological contributor in lung physiology and chronic lung diseases?. Journal of Medical Genetics, 2014, 51, 646-649.	1.5	31
103	Factors associated with humoral immune response to pandemic A/H1N1( $\nu$ ) 2009 influenza vaccine in cystic fibrosis. Vaccine, 2014, 32, 4515-4521.	1.7	9
104	Flagellin concentrations in expectorations from cystic fibrosis patients. BMC Pulmonary Medicine, 2014, 14, 100.	0.8	9
105	Azithromycin analogue <scp>CSY</scp> 0073 attenuates lung inflammation induced by <scp>LPS</scp> challenge. British Journal of Pharmacology, 2014, 171, 1783-1794.	2.7	44
106	Alveolar epithelial cells: Master regulators of lung homeostasis. International Journal of Biochemistry and Cell Biology, 2013, 45, 2568-2573.	1.2	187
107	New insights into pediatric idiopathic pulmonary hemosiderosis: the French RespiRare $\hat{A}^{\otimes}$ cohort. Orphanet Journal of Rare Diseases, 2013, 8, 161.	1.2	95
108	CFTR p.Arg117His associated with CBAVD and other CFTR-related disorders. Journal of Medical Genetics, 2013, 50, 220-227.	1.5	31

#	Article	IF	Citations
109	Anoctamin 1 dysregulation alters bronchial epithelial repair in cystic fibrosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 2340-2351.	1.8	40
110	Endobronchial avium mycobacteria infection in an immunocompetent child. BMJ Case Reports, 2013, 2013, bcr2013200776-bcr2013200776.	0.2	5
111	Pulmonary sarcoid-like granulomatous disease in an 11-month-old girl. BMJ Case Reports, 2013, 2013, bcr2012008024-bcr2012008024.	0.2	2
112	Ancestral haplotype 8.1 and lung disease severity in European cystic fibrosis patients. Journal of Cystic Fibrosis, 2012, 11, 63-67.	0.3	22
113	A national internet-linked based database for pediatric interstitial lung diseases: the French network. Orphanet Journal of Rare Diseases, 2012, 7, 40.	1.2	79
114	Reference percentiles for FEV1 and BMI in European children and adults with cystic fibrosis. Orphanet Journal of Rare Diseases, 2012, 7, 64.	1.2	21
115	Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis. Nature Genetics, 2012, 44, 562-569.	9.4	177
116	AGER -429T/C Is Associated with an Increased Lung Disease Severity in Cystic Fibrosis. PLoS ONE, 2012, 7, e41913.	1.1	36
117	Glucocorticoids reduce inflammation in cystic fibrosis bronchial epithelial cells. Cellular Signalling, 2012, 24, 1093-1099.	1.7	25
118	Evaluation of the trachea and intrathoracic airways by the acoustic reflection method in children with cystic fibrosis. Respiratory Physiology and Neurobiology, 2012, 181, 74-78.	0.7	5
119	A rare CFTR intronic mutation related to a mild CF disease in a 12-year-old girl. BMJ Case Reports, 2012, 2012, bcr2012006918-bcr2012006918.	0.2	6
120	Macrolides: New therapeutic perspectives in lung diseases. International Journal of Biochemistry and Cell Biology, 2011, 43, 1241-1246.	1.2	21
121	149* 2009 H1N1 influenza A in cystic fibrosis patients. A French collaborative study. Journal of Cystic Fibrosis, 2011, 10, S38.	0.3	0
122	Search For Interstitial Lung Disease Etiology In Children: A Step By Step Approach. , 2011, , .		0
123	Interstitial lung disease: Physiopathology in the context of lung growth. Paediatric Respiratory Reviews, 2011, 12, 216-222.	1.2	25
124	Azithromycin In Interstitial Lung Disease Associated With Surfactant Metabolism Disorders. , 2010, , .		0
125	Longitudinal survey of Staphylococcus aureus in cystic fibrosis patients using a multiple-locus variable-number of tandem-repeats analysis method. BMC Microbiology, 2010, 10, 24.	1.3	19
126	The role of LTA4H and ALOX5AP genes in the risk for asthma in Latinos. Clinical and Experimental Allergy, 2010, 40, 582-589.	1.4	31

#	Article	IF	CITATIONS
127	ALOX5AP and LTA4H polymorphisms modify augmentation of bronchodilator responsiveness by leukotriene modifiers in Latinos. Journal of Allergy and Clinical Immunology, 2010, 126, 853-858.	1.5	19
128	Interstitial lung diseases in children. Orphanet Journal of Rare Diseases, 2010, 5, 22.	1.2	112
129	Dramatic Improvement by Macrolides in Surfactant Deficiency with ABCA3 Mutation, 2009, , .		0
130	The very low penetrance of cystic fibrosis for the R117H mutation: a reappraisal for genetic counselling and newborn screening. Journal of Medical Genetics, 2009, 46, 752-758.	1.5	106
131	Lung alveolar epithelium and interstitial lung disease. International Journal of Biochemistry and Cell Biology, 2009, 41, 1643-1651.	1.2	50
132	Azithromycin long term effects in children with cystic fibrosis. Journal of Cystic Fibrosis, 2009, 8, S66.	0.3	0
133	Genetic ancestry modifies pharmacogenetic gene–gene interaction for asthma. Pharmacogenetics and Genomics, 2009, 19, 489-496.	0.7	42
134	Genetic variations in inflammatory mediators influence lung disease progression in cystic fibrosis. Pediatric Pulmonology, 2008, 43, 1224-1232.	1.0	41
135	Circulating and airway neutrophils in cystic fibrosis display different TLR expression and responsiveness to interleukin-10. Cytokine, 2008, 41, 54-60.	1.4	47
136	Pharmacogenetic response to albuterol among asthmatics. Pharmacogenomics, 2008, 9, 505-510.	0.6	21
137	Neutrophils in Cystic Fibrosis Display a Distinct Gene Expression Pattern. Molecular Medicine, 2008, 14, 36-44.	1.9	69
138	Multiple-Locus Variable-Number Tandem-Repeat Analysis for Longitudinal Survey of Sources of <i>Pseudomonas aeruginosa</i> Infection in Cystic Fibrosis Patients. Journal of Clinical Microbiology, 2007, 45, 3175-3183.	1.8	79
139	Glucocorticoid receptor gene polymorphisms associated with progression of lung disease in young patients with cystic fibrosis. Respiratory Research, 2007, 8, 88.	1.4	28
140	Adherence of airway neutrophils and inflammatory response are increased in CF airway epithelial cell-neutrophil interactions. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2006, 290, L588-L596.	1.3	50
141	Mild cystic fibrosis revealed by persistent hyponatremia during the French 2003 heat wave, associated with the S1455X C-terminus CFTR mutation. Clinical Genetics, 2005, 68, 552-553.	1.0	14
142	Influence of Interleukinâ€10 onAspergillus fumigatusInfection in Patients with Cystic Fibrosis. Journal of Infectious Diseases, 2005, 191, 1988-1991.	1.9	115
143	Distinct cytokine production by lung and blood neutrophils from children with cystic fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2003, 284, L997-L1003.	1.3	108
144	SARS-CoV-2 B.1.1.529 (Omicron) Variant Causes an Unprecedented Surge in Children Hospitalizations and Distinct Clinical Presentation Compared to the SARS-CoV-2 B.1.617.2 (Delta) Variant. Frontiers in Pediatrics, 0, 10, .	0.9	14